RADNOR,
Pa., Aug. 13, 2024 /PRNewswire/ -- NRx
Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the
"Company"), a clinical-stage biopharmaceutical company, today
announced that it will release its second quarter and year to date
2024 financial results after the market closes on Wednesday, August 14, 2024, via press release,
which will be available on the Company's website at
https://ir.nrxpharma.com/. The Company will host a conference call
to discuss the financial results as well as provide a corporate
update at 4:30pm ET the same day.
A live webcast of the conference call will be available on the
Company's website at https://ir.nrxpharma.com/events .
Participants that are unable to join the webcast can access the
conference call via telephone by dialing domestically
+1-800-717-1738 or internationally +1-646-307-1865.
About NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals is a clinical-stage biopharmaceutical
company developing therapeutics based on its NMDA platform for the
treatment of central nervous system disorders, specifically
suicidal bipolar depression, chronic pain, and PTSD. The Company is
developing NRX-101, an FDA-designated investigational Breakthrough
Therapy for suicidal treatment-resistant bipolar depression and
chronic pain. NRx plans to file an NDA for Accelerated Approval for
NRX-101 in patients with bipolar depression and suicidality or
akathisia. NRX-101 additionally has potential to act as a
non-opioid treatment for chronic pain, as well as a treatment for
complicated UTI.
NRx has recently announced plans to submit a New Drug
Application for NRX-100 (IV ketamine) for the treatment of suicidal
depression, based on results of well-controlled clinical trials
conducted under the auspices of the US National Institutes of
Health and newly obtained data from French health authorities,
licensed under a data sharing agreement. NRx was awarded Fast Track
Designation for development of ketamine (NRX-100) by the US FDA as
part of a protocol to treat patients with acute suicidality.
About HOPE Therapeutics, Inc.
HOPE Therapeutics, Inc. (www.hopetherapeutics.com) is a
care delivery company developing a best-in-class network of clinics
that currently offer ketamine and other lifesaving therapies to
patients with suicidal depression and related disorders, together
with a digital therapeutic-enabled platform designed to augment and
preserve the clinical benefit of NMDA-targeted drug therapy.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-inc-nasdaq-nrxp-to-report-second-quarter-and-year-to-date-2024-financial-results-on-august-14-2024-302221376.html
SOURCE NRx Pharmaceuticals, Inc.